Mahendra Deonarain

Company: Antikor

Job title: Chief Executive Officer

Seminars:

Applying Fragment Drug Conjugates to Explore Novel Targets 2:30 pm

Fine-tuning our FDC discovery platform to discover antibody fragments and linker payloads tailored for solid tumors Outlining the discovery of Antikor’s lead FDC program (ANT-045) and follow-up programs Reviewing the development of ANT-045 FDC in advanced models for tumor cure efficacy and safetyRead more

day: Conference Day Two